XZP-KM118 (pertuzumab biosimilar) / Sihuan Pharmaceutical, Beijing SL Pharma - LARVOL DELTA

A phase I, randomized, double-blind, parallel, single-dose pharmacokinetic study to evaluate the biosimilarity of KM118 (proposed pertuzumab biosimilar) with reference pertuzumab (Perjeta®) in healthy male subjects. (PubMed, Ann Med) - P1 | "Both formulations were well tolerated. chinaDrugtrials.org.cn, identifier CTR20202566 (December 17, 2020); chictr.org.cn, identifier ChiCTR2400092982 (November 26, 2024)."

Clinical • Journal • PK/PD data

Comparative Study on Pharmacokinetics of KM118 Monoclonal Antibody Injection and pertuzumab Injection (Perjeta®) by Single Intravenous Infusion in Healthy Male Subjects (ChiCTR) - P1 | N=100 | Completed | Sponsor: Beijing shijitan hospital affiliated to capital medical university; Beijing shijitan hospital affiliated to capital medical university

New P1 trial • Breast Cancer • Oncology • Solid Tumor